PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
Francisco Cezar Aquino de MoraesEric PasqualottoLucca Moreira LopesMaria Eduarda Cavalcanti SouzaAnna Luíza Soares de Oliveira RodriguesArtur Menegaz de AlmeidaCarlos SteccaMarianne Rodrigues FernandesNey Pereira Carneiro Dos SantosPublished in: BMC cancer (2023)
Immunotherapy plus carboplatin-paclitaxel increased significantly PFS and OS among patients with advanced or recurrent endometrial cancer, with a significant benefit in the mismatch repair-deficient and high microsatellite instability population.